Search clinical trials for: Denosumab-nivolumab combination

Total 6776 results

M.D. Anderson Cancer Center
Amgen

Terminated

Denosumab for Breast Cancer With Bone Mets

Breast Cancer

United States
Fundació Institut de Recerca de l'Hospital de la...

Completed

The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty

Bone Resorption
Amgen

Completed

Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

Renal Impairment

United States
Shanghai Henlius Biotech

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Postmenopausal

China
Martin Blomberg Jensen

Completed

Denosumab and Male Infertility: a RCT

Infertility, Male

Denmark
Massachusetts General Hospital

Active, not recruiting

Anabolic Therapy in Postmenopausal Osteoporosis

Postmenopausal Osteoporosis

United States
Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Terminated

Denosumab in Primary Hyperparathyroidism

Primary Hyperparathyroidism

United States
Chinese University of Hong Kong

Completed

Effect of Denosumab in Erosion Healing in RA

Rheumatoid Arthritis

China
Children's Hospital of Eastern Ontario

Completed

Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study

Osteoporosis

Canada
Amgen

Completed

A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

Postmenopausal Osteoporosis
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)

Colorectal Cancer Metastatic | MSI-H Colorectal Cancer

France
The First Affiliated Hospital of Hunan University...
University of British Columbia; Ministry of Science and Technology of the People´s...

Unknown

Acupuncture for Insomnia: a Randomized Controlled Trial (AI-RCT)

Sleep Initiation and Maintenance Disorders

China
Case Comprehensive Cancer Center

Withdrawn

Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer

Metastatic Colorectal Cancer
Barbara Burtness

Recruiting

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Squamous Cell Carcinoma of Head and Neck

United States
Ontario Clinical Oncology Group (OCOG)
Bristol-Myers Squibb

Active, not recruiting

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)

Metastatic Renal Cell Carcinoma

Canada, Australia
University of Pittsburgh
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Melanoma

United States
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Australian and New Zealand Intensive Care Research...

Recruiting

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (BoneZone)

Critical Illness | Osteoporosis

Australia, New Zealand
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)

Malignant Melanoma Stage III

United States, Netherlands, Australia
Bristol-Myers Squibb

Completed

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914)

Carcinoma, Renal Cell

United States, Italy, Brazil, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Germany, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland, Turkey, United...
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
Biocon Biologics UK Ltd
Biotrial

Completed

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS (DENARIUS)

Healthy Volunteers

United States
Biocon Biologics UK Ltd

Active, not recruiting

Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis (DEVOTE)

Postmenopausal Women With Osteoporosis

United Kingdom
Amgen
Daiichi Sankyo, Inc.

Completed

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Bone Metastases
Amgen

Completed

Effect of Denosumab on Cellular Biomarkers in the Human Breast

Healthy Volunteer, Female, Breast

United States
Fondazione Ricerca Traslazionale
Clinical Research Technology S.r.l.

Unknown

An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (SQUINT)

Squamous-Cell Lung Cancer

Italy
Taizhou Mabtech Pharmaceutical Co.,Ltd

Recruiting

Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers

Healthy Volunteers

China
Martin Blomberg Jensen

Recruiting

FITMI - First In Treating Male Infertility

Infertility, Male

Denmark
Amgen

Completed

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Bone Metastases
Tuen Mun Hospital

Completed

Denosumab Versus Bisphosphonates (Alendronate) in GIOP

Osteoporosis

China
Amgen

Completed

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Hormone Refractory Prostate Cancer
Amgen

Completed

Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

Postmenopausal Osteoporosis
Shanghai JMT-Bio Inc.

Recruiting

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

China
Shanghai Hansoh Biomedical Co., Ltd

Recruiting

Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults

Postmenopausal Osteoporosis

China
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Active, not recruiting

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

Osteoporosis | Spinal Cord Injuries

United States
Fresenius Kabi SwissBioSim GmbH

Completed

A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

Hungary, Poland, Georgia, Bulgaria, Czechia, Estonia
Peking University People's Hospital

Unknown

Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China

Giant Cell Tumor of Bone
Kyowa Kirin, Inc.
Bristol-Myers Squibb

Completed

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Carcinoma | HCC | Cancer | Hepatocellular Carcinoma | Solid Tumor

United States
Ikena Oncology
Bristol-Myers Squibb

Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Neoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditions

United States
Medical College of Wisconsin

Terminated

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Lymphoma | Myelodysplastic Syndromes | Acute Leukemia | Chronic Leukemia

United States
Bristol-Myers Squibb

Not yet recruiting

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France (URADJ)

Urothelial Carcinoma

France
Meirav Kedmi MD

Recruiting

Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy (NivoM)

Lymphoma, B-Cell

Israel
Massachusetts General Hospital

Active, not recruiting

Comparative Antiresorptive Efficacy Discontinuation of Denosumab

Osteoporosis | Osteoporosis, Postmenopausal

United States
Virginia Commonwealth University
Gilead Sciences

Withdrawn

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (RIVe-CLL/SLL)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
Yale University
AstraZeneca

Withdrawn

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Malignant Melanoma
National Taiwan University Hospital

Completed

Denosumab Sequential Therapy (DST)

Osteoporosis

Taiwan
Amgen

Completed

A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Postmenopausal Osteoporosis
Italian Network for Tumor Biotherapy Foundation
Bristol-Myers Squibb; Astex Pharmaceuticals, Inc.

Not yet recruiting

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)

Melanoma | Non Small Cell Lung Cancer

Italy
Universitätsklinikum Köln
ZKS Köln

Withdrawn

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients (CERAD-IMMUNE)

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Recruiting

Treatment With Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

Osteoporosis | Spinal Cord Injuries

United States

Search clinical trials for: Denosumab-nivolumab combination

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations